Latest Conference Articles

Kapil N. Bhalla, MD, from the University of Kansas Cancer Center, describes an in vivo study that examined treatment with histone deacetylase inhibitors in triple-negative breast cancer cells.

Stefan Aebi, MD, from the Luzerner Kantonsspital, Switzerland, discusses findings from the CALOR trial that examined the administration of adjuvant chemotherapy for women recurrent breast cancer.

Preliminary research suggests that in-vitro exposure to an HDAC inhibitor may sensitize triple-negative breast cancer cells to treatment with a PARP inhibitor and cisplatin.

Adjuvant chemotherapy improved survival rates in women with isolated local or regional breast cancer recurrence, according to results from the CALOR trial.

Postmenopausal women with advanced estrogen receptor–positive breast cancer lived longer when they received a 500-mg dose of fulvestrant as compared with a 250-mg dose.

Combining the investigational PD 0332991 with letrozole as first-line therapy extended progression-free survival in women with advanced estrogen-receptor positive breast cancer.

Sentinel lymph node surgery may provide a less-invasive alternative to axillary lymph node dissection for nodal staging in node-positive breast cancer.

Extending the duration of adjuvant tamoxifen treatment to 10 years was more effective than the standard 5 years of treatment in protecting against recurrence and death among women with ER+ breast cancer.

Judy C. Boughey, MD, from the Mayo Clinic in Rochester, MN, discusses surgical techniques examined in the Z1071 study that could help minimize the false negative rates experienced with SLN surgery.

Richard Finn, MD, from the Jonsson Comprehensive Cancer Center, describes results from a phase II study that examined PD 0332991 in combination with letrozole for women with metastatic ER-positive breast cancer.

After many years of treating patients with advanced prostate cancer the same way, a host of new drug approvals has not only changed the way urologists manage prostate cancer but their understanding of the disease as well.

Michael Rotkowitz, MD, says that one of the main challenges and a leading goal of immunotherapy research is measuring response to justify the administration.

The 2012 LUGPA Annual Meeting is expected to gather more than 100 urology groups to discuss administrative, technological, regulatory, and medical challenges facing practices.

Stephen J. Freedland, MD, from Duke University School of Medicine, discusses the complications faced when treating men with early-stage prostate cancer.

The latest research on several investigational cancer therapies was presented at the European Society for Medical Oncology 2012 Congress.

Photos from the 2012 National Coalition of Oncology Nurse Navigators' (NCONN) annual conference that was held at the Gaylord Opryland Hotel from October 4th to 6th, in Nashville, Tennessee.

The incidence of melanoma, the deadliest of all skin cancers, is quickly rising, and the disease is responsible for more than 8000 deaths each year.

Facilities seeking Commission on Cancer accreditation now need to have a patient navigation process in place by 2015.

Updates on breast cancer risk factors, screening methods, and treatments for the nurse navigators who are guiding patients from diagnosis to treatment and, hopefully, through survivorship.

Cristi Radford, a Certified Genetic Counselor, explains the multifaceted role that oncology nurse navigators play in the genetic counseling process.

Ezra Cohen, MD, from the University of Chicago Medical Center, discusses the impact of cabozantinib's dose size on tolerability.

Photos from the 2012 European Society for Medical Oncology (ESMO) congress, held at the Austria Center Vienna from September 28 to October 2, in Vienna, Austria.

Regorafenib significantly delays disease progression in virtually all subgroups of patients with GIST in the second-line setting, and may even confer benefits when continued after progression.

Nearly twice as many patients with metastatic melanoma who received a combination of ipilimumab and dacarbazine were alive after four years, suggesting that ipilimumab has long-term survival benefits.

Long-term follow-up of the HERA trial confirms that 1 year of adjuvant therapy with trastuzumab should remain the standard of care for treatment of women with HER2-positive invasive early breast cancer.

An exploratory analysis of the phase III AURELIA trial affirms the benefit of adding bevacizumab to chemotherapy for patients with platinum-resistant recurrent ovarian cancer.

The addition of ifosfamide to doxorubicin in the treatment of advanced soft tissue sarcomas delayed disease progression but did not improve survival.

Pazopanib appears to be another good option for first-line therapy of metastatic renal cell carcinoma along with sunitinib.

An updated analysis of the phase III EMILIA trial showed that T-DM1 significantly extended survival in women with HER2-positive, unresectable, locally advanced or metastatic breast cancer.

Crizotinib extended PFS and improved response rates compared with single-agent chemotherapy with pemetrexed or docetaxel in patients with advanced, previously treated, ALK-positive, NSCLC.